etylmetylhydroksypyrydyna | Mexiprim tablets coated with film about 125 mg 60 pcs.
Special Price
$18.43
Regular Price
$27.00
In stock
SKU
BID470535
Release form
125 mg film-coated tablets. On 10 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. On 1, 2, 3, 4 or 6 blister strip packagings together with the application instruction are placed in a cardboard pack.
125 mg film-coated tablets. On 10 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. On 1, 2, 3, 4 or 6 blister strip packagings together with the application instruction are placed in a cardboard pack.
Release form
125 mg film-coated tablets. On 10 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. On 1, 2, 3, 4 or 6 blister strip packagings together with the application instruction are placed in a cardboard pack.
Packing
60 pcs.
Pharmacological action
Pharmacodynamics
Mexiprim refers to heteroaromatic antioxidants. Has a wide range of pharmacological activity: increases the body's resistance to stress, exhibits anxiolytic effect, which is not accompanied by a muscle relaxant effect, has nootropic properties, prevents and reduces learning and memory impairments that occur during aging and exposure to various pathogenic factors, has an anticonvulsant effect, exhibits antioxidant and antihypoxic properties, increases concentration and performance weakens the toxic effect of alcohol.
The drug improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of the blood, reduces platelet aggregation. Stabilizes the membrane structure of blood cells (red blood cells and platelets). It has a lipid-lowering effect, reduces the content of total cholesterol and low density lipoproteins.
The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the ratio of lipid protein, reduces the viscosity of the membrane, increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to preserve the structurally functional organization of biomembranes, and transport neuron. Mexiprim increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy synthesizing functions of mitochondria, stabilization of cell membranes.
Pharmacokinetics of
Mexiprim is rapidly absorbed from the gastrointestinal tract with a half-absorption period of 0.08-0.1 hours. The time to reach maximum plasma concentration is 0.46-0.5 hours. The maximum concentration of Mexiprim in blood plasma is in the range from 50 to 100 ng / ml.
The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively. Mexiprim in the human body is extensively metabolized with the formation of its glucuronoconjugated product. On average, within 12 hours, 0.3% of the unchanged drug and 50% in the form of a glucuronoconjugate from the administered dose are excreted in the urine. Mexiprim and its glucuronoconjugate are excreted most intensively during the first 4 hours after taking the drug. Urinary excretion rates of Mexiprim and its conjugated metabolite have significant individual variability.
Indications
Anxiety disorders in neurotic and neurosis-like conditions
vegetative-vascular dystonia
mild cognitive impairment of various origins (in the case of psycho-organic syndrome and asthenic disorders caused by acute and chronic disorders of the cerebral circulation, neuroinfection and intoxication, senile and atrophic processes)
memory disorders and intellectual deficiency in the elderly
exposure to extreme (stress) factors
alcohol withdrawal syndrome with a predominance of neurosis-like and vegetative-vascular disorders.
Contraindications
Hepatic and / or renal failure, increased individual sensitivity to the drug, children, pregnancy, breastfeeding.
Special instructions
During treatment, care must be taken when driving vehicles and engaging in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.
Dosage and administration of merdiprim
is prescribed orally. The therapeutic doses used and the duration of treatment are determined by the sensitivity of patients to the drug. Treatment begins with a dose of 0.25-0.5 g, the average daily dose is 0.25-0.5 g, the maximum daily dose is 0.8 g. The daily dose of the drug is divided into 2-3 doses throughout the day.
For the treatment of patients with anxiety disorders, autonomic vascular dysfunctions and cognitive impairment, Mexiprim is used for 2-6 weeks. When stopping alcohol withdrawal syndrome, Mexiprim is used within 5-7 days.
Course therapy with Mexiprim is completed gradually, reducing the dose of the drug within 2-3 days.
Side effects
May cause individual adverse reactions: nausea and dry mouth, drowsiness, allergic reactions.
Drug Interactions
Compatible with psychotropic drugs. Enhances the action of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa), reduces the toxic effect of ethyl alcohol.
Overdose
Symptoms: sleep disturbance (insomnia, in some cases drowsiness).
Treatment: usually not required - symptoms disappear on their own within a day. In severe cases with insomnia, it is recommended to take nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.
Storage Conditions
In a dark place at a temperature not exceeding 25 РC.
Expiration
5 years.
active substance
ethylmethylhydroxypyridine succinate
The dosage form of
tablet
Prescribing
Adults as prescribed by a doctor
Indications
Indications
From vegetative-vascular disorders, From the effects of stroke, brain injury, and other injuries , Atherosclerosis, From neurosis, From acquired dementia, From Alzheimer's disease, Cerebrovascular accident
Nizhpharm, Russia
125 mg film-coated tablets. On 10 tablets in a blister strip packaging from a film of polyvinyl chloride and aluminum foil. On 1, 2, 3, 4 or 6 blister strip packagings together with the application instruction are placed in a cardboard pack.
Packing
60 pcs.
Pharmacological action
Pharmacodynamics
Mexiprim refers to heteroaromatic antioxidants. Has a wide range of pharmacological activity: increases the body's resistance to stress, exhibits anxiolytic effect, which is not accompanied by a muscle relaxant effect, has nootropic properties, prevents and reduces learning and memory impairments that occur during aging and exposure to various pathogenic factors, has an anticonvulsant effect, exhibits antioxidant and antihypoxic properties, increases concentration and performance weakens the toxic effect of alcohol.
The drug improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of the blood, reduces platelet aggregation. Stabilizes the membrane structure of blood cells (red blood cells and platelets). It has a lipid-lowering effect, reduces the content of total cholesterol and low density lipoproteins.
The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the ratio of lipid protein, reduces the viscosity of the membrane, increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to preserve the structurally functional organization of biomembranes, and transport neuron. Mexiprim increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy synthesizing functions of mitochondria, stabilization of cell membranes.
Pharmacokinetics of
Mexiprim is rapidly absorbed from the gastrointestinal tract with a half-absorption period of 0.08-0.1 hours. The time to reach maximum plasma concentration is 0.46-0.5 hours. The maximum concentration of Mexiprim in blood plasma is in the range from 50 to 100 ng / ml.
The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively. Mexiprim in the human body is extensively metabolized with the formation of its glucuronoconjugated product. On average, within 12 hours, 0.3% of the unchanged drug and 50% in the form of a glucuronoconjugate from the administered dose are excreted in the urine. Mexiprim and its glucuronoconjugate are excreted most intensively during the first 4 hours after taking the drug. Urinary excretion rates of Mexiprim and its conjugated metabolite have significant individual variability.
Indications
Anxiety disorders in neurotic and neurosis-like conditions
vegetative-vascular dystonia
mild cognitive impairment of various origins (in the case of psycho-organic syndrome and asthenic disorders caused by acute and chronic disorders of the cerebral circulation, neuroinfection and intoxication, senile and atrophic processes)
memory disorders and intellectual deficiency in the elderly
exposure to extreme (stress) factors
alcohol withdrawal syndrome with a predominance of neurosis-like and vegetative-vascular disorders.
Contraindications
Hepatic and / or renal failure, increased individual sensitivity to the drug, children, pregnancy, breastfeeding.
Special instructions
During treatment, care must be taken when driving vehicles and engaging in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.
Dosage and administration of merdiprim
is prescribed orally. The therapeutic doses used and the duration of treatment are determined by the sensitivity of patients to the drug. Treatment begins with a dose of 0.25-0.5 g, the average daily dose is 0.25-0.5 g, the maximum daily dose is 0.8 g. The daily dose of the drug is divided into 2-3 doses throughout the day.
For the treatment of patients with anxiety disorders, autonomic vascular dysfunctions and cognitive impairment, Mexiprim is used for 2-6 weeks. When stopping alcohol withdrawal syndrome, Mexiprim is used within 5-7 days.
Course therapy with Mexiprim is completed gradually, reducing the dose of the drug within 2-3 days.
Side effects
May cause individual adverse reactions: nausea and dry mouth, drowsiness, allergic reactions.
Drug Interactions
Compatible with psychotropic drugs. Enhances the action of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa), reduces the toxic effect of ethyl alcohol.
Overdose
Symptoms: sleep disturbance (insomnia, in some cases drowsiness).
Treatment: usually not required - symptoms disappear on their own within a day. In severe cases with insomnia, it is recommended to take nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.
Storage Conditions
In a dark place at a temperature not exceeding 25 РC.
Expiration
5 years.
active substance
ethylmethylhydroxypyridine succinate
The dosage form of
tablet
Prescribing
Adults as prescribed by a doctor
Indications
Indications
From vegetative-vascular disorders, From the effects of stroke, brain injury, and other injuries , Atherosclerosis, From neurosis, From acquired dementia, From Alzheimer's disease, Cerebrovascular accident
Nizhpharm, Russia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review